FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766373370> ?p ?o ?g. }

• W2766373370 abstract "The development of therapeutic agents for pre-dementia stages of Alzheimer's disease (AD) poses the challenge of selecting homogeneous cohorts of individuals for clinical trials. Trial enrichment via prognostic biomarkers provides one means of doing so. In pre-dementia patients, hippocampal atrophy is associated with progression to dementia. CAMD is pursuing regulatory qualification of baseline intracranial volume-adjusted hippocampal volume (ICV-HV) as an enrichment biomarker in pre-dementia trials, supported by a model-based analysis, through the development of a quantitative description of disease progression. To assess the utility of ICV-HV as a prognostic biomarker for clinical trial enrichment, patient-level data from three sources – the Alzheimer's Disease Neuroimaging Initiative (ADNI)-1 and ADNI-2 observational studies, and the Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx) clinical trial – have been standardized to the Clinical Data Interchange Standards Consortium (CDISC) therapeutic-area standards for AD. Briefing documents and face-to-face meetings have been held with the US FDA to finalize the proposed Context of Use Statement for the biomarker, as well as the intended statistical analysis plan. The analysis dataset, consisting of pre-dementia patient-level data from ADNI-1 (n≈305), late pre-dementia from ADNI-2 (n≈122) and InDDEx (n≈394), has been standardized and curated. Imaging data have been re-processed, and ICV-HV was determined by two image analysis algorithms, namely LEAP™ and FreeSurfer™. As per guidance from FDA, temporal changes in Clinical Dementia Rating Scale Sum-of-Boxes (CDR-SB) will be described by a non-linear mixed-effects model. Along with ICV-HV, sex, baseline age and disease severity, and apolipoprotein E genotype will be included as covariates. Clinical trial simulations using the Monte Carlo technique will be performed to compare the statistical power by sample size in trials with and trials without ICV-HV enrichment. The full qualification document will be submitted to the FDA by 3Q 2017. This ongoing biomarker qualification effort with the FDA highlights the importance of understanding disease progression quantitatively to support the qualification of ICV-HV for prognostic purposes. If ICV-HV demonstrates utility in clinical trial enrichment, qualification of this biomarker can streamline drug development programs in AD by insuring the right patients are enrolled into our trials." @default.
• W2766373370 created "2017-11-10" @default.
• W2766373370 creator A5002528518 @default.
• W2766373370 creator A5010643874 @default.
• W2766373370 creator A5011092770 @default.
• W2766373370 creator A5012892785 @default.
• W2766373370 creator A5016439888 @default.
• W2766373370 creator A5019844576 @default.
• W2766373370 creator A5020696792 @default.
• W2766373370 creator A5024585813 @default.
• W2766373370 creator A5024807342 @default.
• W2766373370 creator A5024979557 @default.
• W2766373370 creator A5033328565 @default.
• W2766373370 creator A5036259423 @default.
• W2766373370 creator A5045300839 @default.
• W2766373370 creator A5058044307 @default.
• W2766373370 creator A5064405735 @default.
• W2766373370 creator A5072891453 @default.
• W2766373370 creator A5083764008 @default.
• W2766373370 creator A5084865929 @default.
• W2766373370 creator A5086549440 @default.
• W2766373370 creator A5021135425 @default.
• W2766373370 date "2017-07-01" @default.
• W2766373370 modified "2023-10-16" @default.
• W2766373370 title "[P4-014]: THE COALITION AGAINST MAJOR DISEASES: TOWARD U.S. FDA QUALIFICATION OF HIPPOCAMPAL VOLUME AS A BIOMARKER FOR ENRICHMENT IN CLINICAL TRIALS FOR PRE-DEMENTIA STAGES OF ALZHEIMER'S DISEASE" @default.
• W2766373370 doi "https://doi.org/10.1016/j.jalz.2017.06.1878" @default.
• W2766373370 hasPublicationYear "2017" @default.
• W2766373370 type Work @default.
• W2766373370 sameAs 2766373370 @default.
• W2766373370 citedByCount "0" @default.
• W2766373370 crossrefType "journal-article" @default.
• W2766373370 hasAuthorship W2766373370A5002528518 @default.
• W2766373370 hasAuthorship W2766373370A5010643874 @default.
• W2766373370 hasAuthorship W2766373370A5011092770 @default.
• W2766373370 hasAuthorship W2766373370A5012892785 @default.
• W2766373370 hasAuthorship W2766373370A5016439888 @default.
• W2766373370 hasAuthorship W2766373370A5019844576 @default.
• W2766373370 hasAuthorship W2766373370A5020696792 @default.
• W2766373370 hasAuthorship W2766373370A5021135425 @default.
• W2766373370 hasAuthorship W2766373370A5024585813 @default.
• W2766373370 hasAuthorship W2766373370A5024807342 @default.
• W2766373370 hasAuthorship W2766373370A5024979557 @default.
• W2766373370 hasAuthorship W2766373370A5033328565 @default.
• W2766373370 hasAuthorship W2766373370A5036259423 @default.
• W2766373370 hasAuthorship W2766373370A5045300839 @default.
• W2766373370 hasAuthorship W2766373370A5058044307 @default.
• W2766373370 hasAuthorship W2766373370A5064405735 @default.
• W2766373370 hasAuthorship W2766373370A5072891453 @default.
• W2766373370 hasAuthorship W2766373370A5083764008 @default.
• W2766373370 hasAuthorship W2766373370A5084865929 @default.
• W2766373370 hasAuthorship W2766373370A5086549440 @default.
• W2766373370 hasBestOaLocation W27663733701 @default.
• W2766373370 hasConcept C118552586 @default.
• W2766373370 hasConcept C126322002 @default.
• W2766373370 hasConcept C126838900 @default.
• W2766373370 hasConcept C143409427 @default.
• W2766373370 hasConcept C143998085 @default.
• W2766373370 hasConcept C151730666 @default.
• W2766373370 hasConcept C185592680 @default.
• W2766373370 hasConcept C2778373026 @default.
• W2766373370 hasConcept C2779134260 @default.
• W2766373370 hasConcept C2779343474 @default.
• W2766373370 hasConcept C2779483572 @default.
• W2766373370 hasConcept C2780906993 @default.
• W2766373370 hasConcept C2781197716 @default.
• W2766373370 hasConcept C45664433 @default.
• W2766373370 hasConcept C535046627 @default.
• W2766373370 hasConcept C55493867 @default.
• W2766373370 hasConcept C58693492 @default.
• W2766373370 hasConcept C71924100 @default.
• W2766373370 hasConcept C86803240 @default.
• W2766373370 hasConceptScore W2766373370C118552586 @default.
• W2766373370 hasConceptScore W2766373370C126322002 @default.
• W2766373370 hasConceptScore W2766373370C126838900 @default.
• W2766373370 hasConceptScore W2766373370C143409427 @default.
• W2766373370 hasConceptScore W2766373370C143998085 @default.
• W2766373370 hasConceptScore W2766373370C151730666 @default.
• W2766373370 hasConceptScore W2766373370C185592680 @default.
• W2766373370 hasConceptScore W2766373370C2778373026 @default.
• W2766373370 hasConceptScore W2766373370C2779134260 @default.
• W2766373370 hasConceptScore W2766373370C2779343474 @default.
• W2766373370 hasConceptScore W2766373370C2779483572 @default.
• W2766373370 hasConceptScore W2766373370C2780906993 @default.
• W2766373370 hasConceptScore W2766373370C2781197716 @default.
• W2766373370 hasConceptScore W2766373370C45664433 @default.
• W2766373370 hasConceptScore W2766373370C535046627 @default.
• W2766373370 hasConceptScore W2766373370C55493867 @default.
• W2766373370 hasConceptScore W2766373370C58693492 @default.
• W2766373370 hasConceptScore W2766373370C71924100 @default.
• W2766373370 hasConceptScore W2766373370C86803240 @default.
• W2766373370 hasIssue "7S_Part_26" @default.
• W2766373370 hasLocation W27663733701 @default.
• W2766373370 hasOpenAccess W2766373370 @default.
• W2766373370 hasPrimaryLocation W27663733701 @default.
• W2766373370 hasRelatedWork W2016273191 @default.
• W2766373370 hasRelatedWork W2031970735 @default.
• W2766373370 hasRelatedWork W2048674585 @default.
• W2766373370 hasRelatedWork W2076738257 @default.
• W2766373370 hasRelatedWork W2139523469 @default.
• W2766373370 hasRelatedWork W2766152896 @default.

• next